Compare · ABBV vs CYRX
ABBV vs CYRX
Side-by-side comparison of AbbVie Inc. (ABBV) and CryoPort Inc. (CYRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and CYRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $351.47B, about 661.2x CYRX ($531.6M).
- Over the past year, ABBV is up 3.3% and CYRX is up 85.7% - CYRX leads by 82.4 points.
- ABBV has been more active in the news (9 items in the past 4 weeks vs 5 for CYRX).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- CryoPort Inc.
- Price
- $198.71-1.12%
- $10.59+3.88%
- Market cap
- $351.47B
- $531.6M
- 1M return
- -4.09%
- +25.86%
- 1Y return
- +3.29%
- +85.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
CryoPort Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Latest ABBV
- AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
- AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
- Canaccord Genuity initiated coverage on AbbVie with a new price target
- AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
- Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
- Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
- AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
- BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year
- Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest CYRX
- President, CEO Shelton Jerrell exercised 104,007 shares at a strike of $1.87, increasing direct ownership by 9% to 1,230,614 units (SEC Form 4)
- SEC Form DEFA14A filed by CryoPort Inc.
- SEC Form DEF 14A filed by CryoPort Inc.
- Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
- SEC Form 4 filed by Shelton Jerrell
- Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.
- SEC Form 4 filed by Stefanovich Robert
- SEC Form 4 filed by Shelton Jerrell
- SEC Form 4 filed by Sawicki Mark W
- Officer Zecchini Edward J was granted 21,322 shares and sold $16,112 worth of shares (2,014 units at $8.00), increasing direct ownership by 21% to 109,719 units (SEC Form 4)